KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

BioNTech SE (BNTX) EBITDA: 2018-2025

Historic EBITDA for BioNTech SE (BNTX) over the last 7 years, with Sep 2025 value amounting to -$59.6 million.

  • BioNTech SE's EBITDA fell 129.06% to -$59.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 billion, marking a year-over-year increase of 8.25%. This contributed to the annual value of -$1.4 billion for FY2024, which is 289.07% down from last year.
  • According to the latest figures from Q3 2025, BioNTech SE's EBITDA is -$59.6 million, which was up 87.61% from -$481.1 million recorded in Q2 2025.
  • In the past 5 years, BioNTech SE's EBITDA ranged from a high of $4.2 billion in Q1 2022 and a low of -$985.8 million during Q2 2024.
  • Over the past 3 years, BioNTech SE's median EBITDA value was -$59.6 million (recorded in 2025), while the average stood at -$144.8 million.
  • In the last 5 years, BioNTech SE's EBITDA soared by 94,870,139.68% in 2021 and then crashed by 396.86% in 2024.
  • Over the past 5 years, BioNTech SE's EBITDA (Quarterly) stood at $272.0 million in 2021, then fell by 16.89% to $226.1 million in 2022, then plummeted by 98.10% to $4.3 million in 2023, then surged by 833.58% to $40.2 million in 2024, then plummeted by 129.06% to -$59.6 million in 2025.
  • Its last three reported values are -$59.6 million in Q3 2025, -$481.1 million for Q2 2025, and -$503.6 million during Q1 2025.